Mycenax Biotech (TWO:4726) — Market Cap & Net Worth
Market Cap & Net Worth: Mycenax Biotech (4726)
Mycenax Biotech (TWO:4726) has a market capitalization of $162.63 Million (NT$5.16 Billion) as of June 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #17445 globally and #900 in its home market, demonstrating a -8.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mycenax Biotech's stock price NT$24.90 by its total outstanding shares 207302900 (207.30 Million). Review debt load of Mycenax Biotech to assess the company's total debt and financial obligations.
Mycenax Biotech Market Cap History: 2015 to 2026
Mycenax Biotech's market capitalization history from 2015 to 2026. Data shows change from $314.80 Million to $162.63 Million (-4.16% CAGR).
Mycenax Biotech Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mycenax Biotech's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.41x
Mycenax Biotech's market cap is 0.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $172.10 Million | $318.64 Million | -$188.37 Million | 0.54x | N/A |
| 2018 | $168.50 Million | $211.42 Million | -$274.43 Million | 0.80x | N/A |
| 2019 | $152.18 Million | $390.84 Million | -$218.18 Million | 0.39x | N/A |
| 2020 | $210.30 Million | $665.34 Million | $30.95 Million | 0.32x | 6.80x |
| 2021 | $247.53 Million | $774.27 Million | -$89.86 Million | 0.32x | N/A |
| 2022 | $244.92 Million | $732.28 Million | -$453.63 Million | 0.33x | N/A |
| 2023 | $233.16 Million | $652.62 Million | -$682.85 Million | 0.36x | N/A |
| 2024 | $283.45 Million | $683.92 Million | -$467.12 Million | 0.41x | N/A |
Competitor Companies of 4726 by Market Capitalization
Companies near Mycenax Biotech in the global market cap rankings as of June 19, 2026.
Key companies related to Mycenax Biotech by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Mycenax Biotech Historical Marketcap From 2015 to 2026
Between 2015 and today, Mycenax Biotech's market cap moved from $314.80 Million to $ 162.63 Million, with a yearly change of -4.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$162.63 Million | -21.20% |
| 2025 | NT$206.39 Million | -27.19% |
| 2024 | NT$283.45 Million | +21.57% |
| 2023 | NT$233.16 Million | -4.80% |
| 2022 | NT$244.92 Million | -1.06% |
| 2021 | NT$247.53 Million | +17.70% |
| 2020 | NT$210.30 Million | +38.20% |
| 2019 | NT$152.18 Million | -9.69% |
| 2018 | NT$168.50 Million | -2.09% |
| 2017 | NT$172.10 Million | -22.50% |
| 2016 | NT$222.06 Million | -29.46% |
| 2015 | NT$314.80 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Mycenax Biotech was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $162.63 Million USD |
| MoneyControl | $162.63 Million USD |
| MarketWatch | $162.63 Million USD |
| marketcap.company | $162.63 Million USD |
| Reuters | $162.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more